

## 10. Literaturverzeichnis

- 1) Almenar L, Maeso ML, Martinez-Dolz L, Rueda J, Palomar CG, Saez AO, Vives MA, Tort MD, Perez MP. Influence of HLA matching on survival in heart transplantation. *Transplant Proc.* 2005; 37(9):4001-5.
- 2) Aziz S, McDonald TO, Gohra H. Transplant arterial vasculopathy: evidence for a dual pattern of endothelial injury and the source of smooth muscle cells in lesions of intimal hyperplasia. *J Heart Lung Transplant.* 1995; 14(6 Pt 2):123-36.
- 3) Aziz TM, Sheldon S, El-Gamel A, Krysiak P, Campbell C, Rahman A, Dyer P, Yonan N, Deiraniya A. Implication of HLA mismatch in the clinical outcome of orthotopic heart transplantation. *Transplantation Proc* 1998; 30:1917-19.
- 4) Bacal F, Sodre GL, Fernandes DA, Aiello VD, Stolf N, Bocchi E, Bellotti G. Methotrexate in acute persistent humoral rejection: an option for graft rescue. *Ann Thorac Surg.* 2003; 76(2):607-10.
- 5) Banner NR, Yacoub MH. Cyclosporine in thoracic organ transplantation. *Transplant Proc.* 2004; 36(2):302-308.
- 6) Billingham ME, Cary NRB, Hammond ME et al. A working formulation for the standardisation of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. *J Heart Transplant* 1990; 9:587-93.
- 7) Billingham ME. Pathology and etiology of chronic rejection of the heart. *Clin Transplant.* 1994; 8(3 Pt 2):289-92.
- 8) Benoist C, Mathis D. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. *Annu. Rev Immunol* 1990; 8:681-715.
- 9) Bodmer JG, Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Hansen JA, Mach B, Mayr WR, Parham P, Petersdorf EW, Sasazuki T, Schreuder GM, Strominger JL, Svejgaard A, Terasaki PI. Nomenclature for factors of the HLA system, 1998. *Tissue Antigens.* 1999; 53(4 Pt 2):407-46.
- 10) Burrig KF. The endothelium of advanced arteriosclerotic plaques in humans. *Arterioscler Thromb.* 1991; 11(6):1678-89.
- 11) Canter C, Naftel D, Caldwell R, Chinnock R, Pahl E, Frazier, Kirklin J, Boucek M, Morrow R. Survival and risk factors for death after cardiac transplantation in infants. A multi-institutional study. *Circulation* 1997; 96:227-231.

- 12) Castellot JJ, Addonizio ML, Rosenberg R, Karnovsky MJ. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. *J Cell Biol* 1981; 90:372.
- 13) Chinnock RE, Larsen RL, Emery JR, Bailey LL. Pretransplant risk factors and causes of death or graft loss after heart transplantation during early infancy. *Circulation* 1995; 92(9):206-209.
- 14) Cochrane A, Benson E, Williams T, Bergin P, Esmore D. Effect of HLA-DR matching on rejection after cardiac transplantation. *Transplant Proc* 1992; 24: 169-70.
- 15) Costanzo MR, Naftel DC, Pritzker MR, Heilman JK 3rd, Boehmer JP, Brozena SC, Dec GW, Ventura HO, Kirklin JK, Bourge RC, Miller LW. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. *Cardiac Transplant Research Database. J Heart Lung Transplant.* 1998; 17(8):744-53.
- 16) Ciubotariu R, Liu Z, Colovai AI, Ho E, Itescu S, Ravalli S, Hardy MA, Cortesini R, Rose EA, Suciuc-Foca N. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. *J Clin Invest.* 1998; 101(2):398-405.
- 17) De Mattos AM, Head MA, Everett J, Hosenpud J, Hershberger R, Cobanoglu A, Ott G, Ratkovec R, Norman DJ. HLA-DR mismatching correlates with early cardiac allograft rejection, incidence, and graft survival when high-confidence-level serological DR typing is used. *Transplantation.* 1994; 57(4):626-30.
- 18) DiSesa VJ, Kuo PC, Horvath KA, Mudge GH, Collins JJ Jr, Cohn LH. HLA histocompatibility affects cardiac transplant rejection and may provide one basis for organ allocation. *Ann Thorac Surg* 1990; 49:220-23.
- 19) Dittrich HC, Shabetai R. Myocardial Biopsy-Techniques, Indications and Complications (1997). In: Peterson KL, Nicod P (Hrsg.): *Cardiac Catheterization-Methods, Diagnosis and Therapy.* W.B. Saunders Company; Philadelphia, S 266-272.
- 20) Doelling NR, Kanter KR, Sullivan KM, Winn KJ, Vincent RN. Medium-term results of pediatric patients undergoing orthotopic heart transplantation. *J Heart Lung Transplant* 1997; 16:1225-1230.
- 21) Druml W. The beginning of organ transplantation: Emerich Ullmann (1861-1937). *Wien Klin Wochenschr.* 2002; 114(4):128-37.

- 22) Dunn M, Crisp S, Rose M, et al. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. *Lancet*. 1992; 339(8809):1566-70.
- 23) Erber WN, Pinching AJ, Mason DY. Immunocytochemical detection of T and B cell populations in routine blood smears. *Lancet* 1984 ;i:1042-5.
- 24) Falini B, Martelli F, Tarallo F, Moir DJ, Cordell JL, Gatter KC, et al. Immunohistological analysis of human bone marrow trephine biopsies using monoclonal antibodies. *Br J Haematol* 1984; 56:365-86.
- 25) Frist WH, Oyer PE, Baldwin JC, Stinson EMB, Shumway NE. HLA compatibility and cardiac recipient survival. *Ann Thorac Surg* 1987; 44:242-46.
- 26) Gao SZ, Hunt SA, Schroeder JS, Alderman E, Hill IR, Stinson EB. Does rapidity of development of transplant coronary artery disease portend a worse prognosis? *J Heart Lung Transplant*. 1994; 13(6):1119-24.
- 27) Gayle L, Winters MD. The Pathology of Heart Allograft Rejection. *Arch Pathol Lab Med* 1991; 115:266-72.
- 28) Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. *JAMA*. 1989; 261(24):3561-6.
- 29) Grossi P, De Maria R, Caroli A, et al. Infections in heart transplant recipients: the experience of the Italian heart transplantation program. Italian Study Group on Infections in Heart Transplantation. *J Heart Lung Transplant*. 1992; 11(5):847-66.
- 30) Haddad M, Pflugfelder PW, Guiraudon C, Novick RJ, McKenzie FN, Menkis A, Kostuk WJ. Angiographic, pathologic, and clinical relationships in coronary artery disease in cardiac allografts. *J Heart Lung Transplant*. 2005; 24(9):1218-25.
- 31) Harding CV, Unanue ER. Cellular mechanisms of antigen processing and the function of class I and II major histocompatibility complex molecules. *Cell Regul*. 1990; 1(7):499-509.
- 32) Hiemann NE, Meyer R, Hummel M, Wellnhofer E, Thomann S, Hetzer R. Role of B cells and macrophages in microvascular disease after heart transplantation. *Thorac Cardiovasc Surg*. 2004; 52(1):16-22.

- 33) Holweg CT, Peeters AM, Balk AH, Uitterlinden AG, Niesters HG, Maat AP, Weimar W, Baan CC. Effect of HLA-DR matching on acute rejection after clinical heart transplantation might be influenced by an IL-2 gene polymorphism. *Transplantation* 2002; 72(8):1353-6.
- 34) Holzkecht ZE, Kuypers KL, Plummer TB, Williams J, Bustos M, Gores GJ, Brunn GJ, Platt JL. Apoptosis and cellular activation in pathogenesis of acute vascular rejection. *Circ Res* 2002; 91(12):1135-41.
- 35) Hornick P, Smith J, Pomeroy A, Banner N, Mitchell A, Rose M, Yacoub M. Influence of donor/recipient phenotype and degree of HLA mismatch on the development of transplant-associated coronary artery disease in heart transplant patients. *Transplantation Proc* 1997; 29:1420-21.
- 36) Horwitz PA, Tsai EJ, Putt ME, Gilmore JM, Lepore JJ, Parmacek MS, Kao AC, Desai SS, Goldberg LR, Brozena SC, Jessup ML, Epstein JA, Cappola TP. Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. *Circulation* 2004; 111(25):3815-3821.
- 37) Hosenpud JD, Shipley J, Wagner C. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. *J Heart Lung Transplant*. 1992; 11(1):9-23.
- 38) Hruban RH, Beschoner WE, Baumgartner WA, Augustine SM, Ren H, Reitz BA, Hutchins GM. Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis. *Am J Pathol*. 1990; 137(4):871-82.
- 39) Hsu RB, Fang CT, Chang SC, Chou NK, Ko WJ, Wang SS, Chu SH. Infectious complications after heart transplantation in Chinese recipients. *Am J Transplant*. 2005; (8):2011-6.
- 40) Jahania MS, Sanchez JA, Narayan P, Lasley RD, Mentzer RM Jr. Heart preservation for transplantation: principles and strategies. *Ann Thorac Surg*. 1999; 68(5):1983-7.
- 41) Johnson DE, Alderman EL, Schroeder JS. Transplant coronary artery disease: histopathologic correlations with angiographic morphology. *J Am Coll Cardiol*. 1991; 17(2):449-57.
- 42) Johnson MR. Transplant coronary disease: nonimmunologic risk factors. *J Heart Lung Transplant*. 1992; 11(3 Pt 2):S124-32.

- 43) Kaczmarek I, Deutsch MA, Rohrer ME, Beiras-Fernandez A, Groetzner J, Daebritz S, Schmoeckel M, Spannagl M, Meiser B, Reichart B. HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies? *J Heart Lung Transplant*. 2006; 25(9):1057-62.
- 44) Kaczmarek I, Landwehr P, Groetzner J, Meiser B, Ueberfuhr P, Reichart B. HLA –DR matching improves survival after heart transplantation-is it time to change allocation policies? *J Heart Lung Transplant* 2005; 24(11):69-70.
- 45) Kaczmarek I, Sadoni S, Schmoeckel M, Lamm P, Daebritz S, Ueberfuhr P, Meiser B, Reichart B. The need for a tailored immunosuppression in older heart transplant recipients. *J Heart Lung Transplant* 2005; 24(11):1965-1968.
- 46) Koch A, Bingold TM, Oberlander J, Sack FU, Otto HF, Hagl S, Schnabel PA. Capillary endothelia and cardiomyocytes differ in vulnerability to ischemia/reperfusion during clinical heart transplantation. *Eur J Cardiothorac Surg* 2001; 20(5):996-1001.
- 47) Kocher AA, Dockal M, Weigel G, Griessmacher A, Grimm M, Ehrlich M, Schlechta B, Cartes-Zumelzu F, Zuckermann A, Splitter A, Roth E, Heismayr M, Laufer G, Wolner E. Immune monitoring in cardiac transplant recipients. *Transplantation Proc* 1997; 29:2895-98.
- 48) Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. *Swiss Med Wkly*. 2001; 131(3-4):41-6.
- 49) Labarrere CA, Deng MC. Microvascular prothrombogenicity and transplant coronary artery disease. *Transpl Immunol* 2002; 9(2-4):243-9.
- 50) Labarrere CA, Nelson DR, Faulk WP: Endothelial activation and development of coronary artery disease in transplanted human hearts. *J Am Med Ass* 1997; 278:1169-75.
- 51) Labarrere CA, Nelson DR, Pitts DE, Kirlin PC, Halbrook H. Immunohistochemical model to predict risk for coronary artery disease and failure in heart transplant patients. *Am J Transplant* 2001; 1(3):251-9.
- 52) Labarrere CA, Pitts D, Nelson DR, Faulk WP. Coronary artery disease in cardiac allografts: Association with arteriolar endothelial HLA-DR and ICAM-1 antigens. *Transplant Proc* 1995; 27(3):1939-40.
- 53) Lansman SL, Ergin MA, Griep RB. The history of heart and heart-lung transplantation. *Cardiovasc Clin*. 1990; 20(2):3-19.

- 54) Laufer G, Miholic J, Laczkovics A, et al. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression. *J Thorac Cardiovasc Surg* 1989; 98:1113-21.
- 55) Leivestad T, Foerster A, Simonsen S, Bratlie A, Thorsby E, Geiran O. HLA-DR matching reduces rejection rate in heart transplantation. *Transpl Int.* 1996; 9 Suppl 1:S230-3.
- 56) Linden MD, Torres FX, Kubus J, Zarbo RJ. Clinical Application of Morphologic and Immunocytochemical Assessments of Cell Proliferation. *Am J Clin Pathol* 1992; 97:4-13.
- 57) Liu Z, Colovai AI, Tugulea S, et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. *J Clin Invest.* 1996; 98(5):1150-7.
- 58) Marsh SG. HLA class II region sequences. *Tissue Antigens.* 1998; 51(4 Pt 2):467-507.
- 59) McDonald K, Rector TS, Braulin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. *Am J Cardiol.* 1989; 64(5):359-62.
- 60) McDouall RM, Batten P, McCormack A, Yacoub MH, Rose ML. MHC class II expression on human heart microvascular endothelial cells: exquisite sensitivity to interferon-gamma and natural killer cells. *Transplantation.* 1997; 64(8):1175-80.
- 61) McManus BM, Horley KJ, Wilson JE, Malcom GT, Kendall TJ, Miles RR, Winters GL, Costanzo MR, Miller LL, Radio SJ. Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy. *Am J Pathol.* 1995; 147(2):293-308.
- 62) Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, Reed, EF, Fishbein MC. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. *J Heart Lung Transplant* 2003; 22(1):58-69.
- 63) Miller LW, Naftel DC, Bourge RC, Kirklin JK, Brozena SC, Jarcho J, Hobbs RE, Mills RM. Infection after heart transplantation: a multiinstitutional study. Cardiac Transplant Research Database Group. *J Heart Lung Transplant.* 1994; 13(3):381-92.

- 64) Minami K, von Knyphausen E, Niino T, Blanz U, Tenderich G, Wlost S, Meyer H, Korfer R. Long-term results of pediatric heart transplantation. *Ann Thorac Cardiovasc Surg.* 2005; 11(6):386-90.
- 65) Mugge A, Brandes RP, Heublein B, Nolte C, Haverich A, Lichtlen PR. Endothelial dysfunction in heart transplanted patients with graft vasculopathy. *Eur Heart J.* 1995; 16 Suppl J: 78-83.
- 66) Naverrete CV. The HLA system in blood transfusion. *Baillière's Clin Haematol* 2000; 13:511-532.
- 67) O'Neill JO, Taylor DO, Starling RC. Immunosuppression for cardiac transplantation--the past, present and future. *Transplant Proc.* 2004; 36(2):309-313.
- 68) Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. *N Engl J Med* 1994; 330:816-19.
- 69) Paul LC. Chronic rejection of organ allografts: magnitude of the problem. *Transplant Proc.* 1993; 25(2):2024-5.
- 70) Pfeffer PF, Foerster A, Froysaker T, Simonsen S, Thorsby E. HLA-DR mismatch and histologically evaluated rejection episodes in cardiac transplants can be correlated. *Transplant Proc* 1988; 20: 367-68.
- 71) Plante GE. Vascular response to stress in health and disease. *Metabolism* 2002; 51(6):25-31.
- 72) Pober JS: Immunobiology of human vascular endothelium. *Immunol Res* 1999; 19:225-32.
- 73) Rabin BS, Griffith BP, Hardesty RL. Vascular endothelial cell HLA-DR antigen and myocyte necrosis in human allograft rejection. *J Heart Transplant.* 1985; 4(3):293-5.
- 74) Raffoux C, Mayor V, Cabrol C, Busson M, Hors J, Colombani J. The influence of HLA matching in cardiac allograft recipients in a single center. *Transplant Proc* 1987; 19:3559-60.
- 75) Reichart B (1987) Geschichtliche Vorbemerkungen. In: Schulz RS (Hrsg) Herz- und Herz- Lungentransplantation. Orthotope und heterotope Techniken. Verlag R. S. Schulz, Percha/ Kempfenhausen am Starnberger See, S 11-27.
- 76) Rose AG, Cooper DK. A histopathologic grading system of hyperacute (humoral, antibody-mediated) cardiac xenograft and allograft rejection. *J Heart Lung Transplant* 1996; 15:804-817.

- 77) Rose AG, Uys CJ, Losman JG, Barnard CN. Evaluation of endomyocardial biopsy in the diagnosis of cardiac rejection. A study using bioptome samples of formalin-fixed tissue. *Transplantation* 1978; 26:10-3.
- 78) Rose M, Navarette C, Yacoub M, Festenstein H. Persistence of donor-specific class II antigens in allografted human heart two years after transplantation. *Hum Immunol* 1988; 23:179-90.
- 79) Rose ML, Coles MI, Griffin RJ, Pomerance A, Yacoub MH. Expression of class II major histocompatibility antigens in normal and transplanted human heart. *Transplantation* 1986; 41:776-80.
- 80) Salomon RN, Hughes CC, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. *Am J Pathol.* 1991; 138(4):791-8.
- 81) Sarris GE, Smith JA, Bernstein D, Griffin ML, Pitlick PT, Baum D, Billingham ME, Oyer PE, Stinson EB, Starnes VA, Shumway NE, Reitz BA. Pediatric cardiac transplantation. The Stanford experience. *Circulation* 1994; 90(2):51-55.
- 82) Scheld HH, Deng MC, Hammel D, Schmid C (2001) Spenderorganqualität. In: *Leitfaden Herztransplantation*. Steinkopff Verlag, Darmstadt, S 77-79.
- 83) Scheld HH, Deng MC, Hammel D, Schmid C (2001) Pathologie nach Transplantation. In: *Leitfaden Herztransplantation*. Steinkopff Verlag, Darmstadt, S 164-172.
- 84) Schowengerdt KO, Naftel DC, Seib PM, Pearce FB, Addonizio LJ, Kirklin JK, Morrow RW. Infection after Pediatric Heart Transplantation: Results of a Multiinstitutional Study. *J Heart Lung Transplant* 1997; 16:1207-1216.
- 85) Sharples LD, Jackson CH, Parameshwar J, Wallwork J, Large SR. Diagnostic accuracy of coronary angiography and risk factors for post-heart-transplant cardiac allograft vasculopathy. *Transplantation* 2003; 76(4):679-82.
- 86) Sheldon S, Hasleton PS, Yonan NA, Rhaman AN, Deiraniya AK, Campbell CS, Brooks NH, Dyer PA. Rejection in heart transplantation strongly correlates with HLA-DR antigen mismatch. *Transplantation* 1994; 6: 719-722.
- 87) Sheldon S, Poulton K. HLA typing and its influence on organ transplantation. *Methods Mol Biol.* 2006; 333:157-74.



- 88) Sherman-Weber S, Axelrod P, Suh B, Rubin S, Beltramo D, Manacchio J, Furukawa S, Weber T, Eisen H, Samuel R. Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literature. *Transpl Infect* 2004; 6(4):165-70.
- 89) Shi C, Lee WS, He Q, Zhang D, Fletcher DL Jr, Newell JB, Haber E. Immunologic basis of transplant-associated arteriosclerosis. *Proc Natl Acad Sci U S A*. 1996; 93(9):4051-6.
- 90) Smith JD, Rose ML, Pomerance A, Burke M, Yacoub M. Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching. *Lancet* 1995; 346:1318-22.
- 91) Spiegelhalter DJ, Stovin PG. An analysis of repeated biopsies following cardiac transplantation. *Stat Med*. 1983; 2(1):33-40.
- 92) Suciu-Foca N, Ciubotariu R, Itescu S, Rose EA, Cortesini R. Indirect allorecognition of donor HLA-DR peptides in chronic rejection of heart allografts. *Transplantation Proc* 1998; 30:3999-4000.
- 93) Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Foca N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *J Heart Lung Transplant* 2005; 24(11):1710-1720.
- 94) St Goar FG, Pinto FJ, Alderman EL, Valantine HA, Schroeder JS, Gao SZ, Stinson EB, Popp RL. Intracoronary ultrasound in cardiac transplant recipients. In vivo evidence of "angiographically silent" intimal thickening. *Circulation*. 1992; 85:979-987.
- 95) Tambur AR, Pamboukian SV, Costanzo MR, Herrera ND, Dunlap S, Montpetit M, Heroux A. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. *Transplantation* 2005; 80(8):1019-1025.
- 96) Tay SS, McCormack A, Rose ML. Effect of cognate human CD4+ T cell and endothelial cell interactions upon chemokine production. *Transplantation*. 2004; 78(7):987-94.

- 97) Thompson J, Thacker L. Effect of HLA-DR and class I cross-reactive group matching on first cardiac transplants: an analysis of access and outcome. *Transplantation Proc* 1998; 30:729.
- 98) Tilney NL, Paz D, Ames J, Gasser M, Laskowski I, Hancock WW. Ischemia-reperfusion injury. *Transplant Proc.* 2001; 33(1-2):843-4.
- 99) Tugulea S, Ciubotariu R, Colovai AI, Liu Z, Itescu S, Schulman LL, Fisher PE, Hardy MA, Rose EA, Michler RE, Cortesini R, Suciu-Foca N. New strategies for early diagnosis of heart allograft rejection. *Transplantation.* 1997; 64(6):842-7.
- 100) Tuzcu EM, Hobbs RE, Rincon G, Bott-Silverman C, De Franco AC, Robinson K, McCarthy PM, Stewart RW, Guyer S, Nissen SE. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation. Insights from intravascular ultrasound. *Circulation* 1995; 91:1706-13.
- 101) Valantine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". *Transplantation* 2003; 76(6):892-9.
- 102) van Loosdregt J, van Oosterhout MF, Bruggink AH, van Wichen DF, van Kuik J, de Koning E, Baan CC, de Jonge N, Gmelig-Meyling FH, de Weger RA. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. *Circulation.* 2006; 114(15):1599-607.
- 103) Vasilescu ER, Ho EK, de la Torre L, Itescu S, Marboe C, Cortesini R, Suciu-Foca N, Mancini D. Anti-HLA antibodies in heart transplantation. *Transpl Immunol.* 2004; 12(2):177-83.
- 104) Vassalli G, Gallino A, Weis M, von Scheidt W, Kappenberger L, von Segesser LK, Goy JJ; Working Group Microcirculation of the European Society of Cardiology. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. *Eur Heart J.* 2003; 24(13):1180-8.
- 105) Ventura HO, Mehra MR, Smart FW, Stapleton DD. Cardiac allograft vasculopathy: current concepts. *Am Heart J.* 1995; 129(4):791-9.
- 106) Weis M, Hartmann A. Transplant vasculopathy following heart transplantation. *Dtsch Med Wochenschr.* 1995; 120(39):1327-33.
- 107) Weis M, Pehlivanli S, von Scheidt W. Heart allograft endothelial cell dysfunction. Cause, course, and consequences. *Z Kardiol.* 2000; 89 Suppl 9: IX/58-62.

- 108) Weis M, von Scheidt W: Coronary artery disease in the transplanted heart. *Annu Rev Med* 2000; 51:81-100.
- 109) Weis M, von Scheidt W. Cardiac allograft vasculopathy-a review. *Circulation* 1997; 96:2069-77.
- 110) Xydas S, Yang JK, Burke EM, Chen JM, Addonizio LJ, Mital SR, Itescu S, Hsu DT, Lamour J. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac Transplant recipients. *J Heart Lung Transplant* 2005; 24(9):1289-1296.
- 111) Yamamoto S, James TN, Kawamura K, Nobuyoshi M. Cardiocytic apoptosis and capillary endothelial swelling as morphological evidence of myocardial ischemia in ventricular biopsies from patients with angina and normal coronary arteriograms. *Coron Artery Dis* 2002; 13(1):25-35.
- 112) Zerbe TR, Arena VC, Kormos RL, Griffith BP, Hardesty RL, Duquesnoy RJ. Histocompatibility and other risk factors for histological rejection of human cardiac allografts during the first three months following transplantation. *Transplantation* 1991; 52:485-90.